Findings

What do systematic reviews say?

676 questions · 705 findings · 98 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 183 · 26%GRADE not reported 47 · 6.7%Very low 209 · 29.6%Low 153 · 21.7%Moderate 85 · 12.1%High 28 · 4%

BM‐MSC vs no treatment

Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

The review found no eligible studies for this question.

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BM‐MSC vs no treatment

Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low

BM‐MSC vs no treatment

Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 1.07 [0.94, 1.22]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.86 [0.62, 1.19]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.47 [0.13, 1.72]
1 study · 64 participants
Low

Intervention not reported

Success of prosthetic rehabilitation (preference) (1 day) · adults over the age of 50 with a unilateral transfemoral amputation

1 finding from 1 review

Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Intervention not reported

Adverse effects (1 day) · adults over the age of 50 with a unilateral transfemoral amputation

The review found no eligible studies for this question.

1 finding from 1 review

Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bad lung down vs good lung down

Hypoxaemia · critically ill adult patients with unilateral lung disease

1 finding from 1 review

Lateral positioning for critically ill adult patients 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19 participants
Low

Bad lung down vs good lung down

Global indicators of tissue oxygenation impairment Arterial‐venous oxygen content difference (C(a‐v)O2) ‐ not reported · critically ill adult patients with unilateral lung disease

1 finding from 1 review

Lateral positioning for critically ill adult patients 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
GRADE not reported

Surgical vs non‐surgical treatment

Split renal function (SRF; · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction

1 finding from 1 review

Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Surgical vs non‐surgical treatment

Drainage pattern ( · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction

1 finding from 1 review

Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 57 participants
Very low

Surgical vs non‐surgical treatment

Upper urinary tract dilatation ( · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction

1 finding from 1 review

Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Surgical vs non‐surgical treatment

UPJO‐associated clinical symptoms · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction

1 finding from 1 review

Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Overall USN at discharge Barrage; Letter Cancellation; Sentence Reading; Wundt‐Jastrow Paolucci 2010 study · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Overall USN at · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Disabilities Rivermead Mobility Index Score Paolucci 2010 study · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Disabilities Rivermead Mobility Index Score Paolucci 2010 study · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Daily life functions Barthel Index score Paolucci 2010 study · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Daily life functions Barthel Index score Paolucci 2010 study · unilateral spatial neglect after stroke

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Intervention not reported

Overall USN Shape cancellation, letter cancellation, and Bells' cancellation Lucas 2013 study · unilateral spatial neglect after stroke

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for unilateral spatial neglect after stroke 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found